196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
19 citations
,
July 2019 in “Journal of Endocrinology” GTx-024 and Danazol affect the uterus like DHT, while GTx-007 has little impact.
August 2024 in “Latin American Journal of Development” 5α-reductase enzymes are crucial in certain disorders, and while treatment advances exist, more research on SRD5A3 is needed.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” Targeting the AhR pathway may help treat alopecia areata.
January 2026 in “Journal of the American Academy of Dermatology” Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
93 citations
,
January 2000 in “Annals of Medicine” Mutations in the androgen receptor gene cause various disorders.
3 citations
,
August 2010 in “Letters in Drug Design & Discovery” 1 citations
,
March 2023 in “Journal of the American College of Cardiology”
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
April 2024 in “Anais Brasileiros de Dermatologia” 3 citations
,
October 2019 in “EMBO molecular medicine” Targeting NCoR1 can help treat heart enlargement and dysfunction.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
February 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” Retinoic acid reduces cell damage from oxidative stress.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
33 citations
,
November 1994 in “Archives of Biochemistry and Biophysics” 50 citations
,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
June 2006 in “Annales de Dermatologie et de Vénéréologie” Tranexamic acid effectively reduced swelling episodes in a girl with a rare form of hereditary angioneurotic edema.
40 citations
,
November 2009 in “Experimental Dermatology” The mineralocorticoid receptor may play a role in skin and hair health and could be a new target for treating related disorders.
4 citations
,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
1 citations
,
September 2023 in “JCEM case reports” GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.
March 2026 in “Journal of the American Academy of Dermatology”
60 citations
,
August 2008 in “Human molecular genetics online/Human molecular genetics” A position effect on the TRPS1 gene causes excessive hair growth in humans and mice.
March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
March 2021 in “Research Square (Research Square)” Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.
Deuruxolitinib is approved to treat severe alopecia areata in adults.